Lavipharm S.A. (ATH:LAVI)

Market Cap	134.62M
Revenue (ttm)	54.66M
Net Income (ttm)	3.87M
Shares Out	168.69M
EPS (ttm)	0.02
PE Ratio	68.97
Forward PE	n/a
Dividend	0.02 (2.51%)
Ex-Dividend Date	Jul 17, 2025

Volume	692,921
Average Volume	262,105
Open	0.7800
Previous Close	0.7810
Day's Range	0.7560 - 0.8000
52-Week Range	0.6500 - 0.9120
Beta	1.18
RSI	45.44
Earnings Date	Nov 17, 2025

About Lavipharm

Lavipharm S.A. engages in the research, development, manufacture, import, marketing, sale, and wholesale of pharmaceutical, cosmetics, and healthcare products to physicians and pharmacists in Greece and internationally. The company offers pharmaceutical products for cardiology, oncology-urology, central nervous system, chronic pain, and self- treatment. It also provides prescription medicines and over the counter (OTC) products, as well as LIFELAB CBD products. The company was founded in 1911 and is based in Paiania, Greece.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1911
• Employees: 299
• Stock Exchange: Athens Stock Exchange
• Ticker Symbol: LAVI

Financial Performance

In 2024, Lavipharm's revenue was 52.95 million, an increase of 10.68% compared to the previous year's 47.84 million. Earnings were 8.98 million, an increase of 380.06%.